Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases
Conferences
Duke, L; Rittiner, J; O'donovan, B; Chiba-Falek, O; Kantor, B
Published in: MOLECULAR THERAPY
May 8, 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
May 8, 2026
Volume
34
Issue
5
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
Citation
APA
Chicago
ICMJE
MLA
NLM
Duke, L., Rittiner, J., O’donovan, B., Chiba-Falek, O., & Kantor, B. (2026). Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases. In MOLECULAR THERAPY (Vol. 34).
Duke, Leanne, Joseph Rittiner, Bernadette O’donovan, Ornit Chiba-Falek, and Boris Kantor. “Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases.” In MOLECULAR THERAPY, Vol. 34, 2026.
Duke L, Rittiner J, O’donovan B, Chiba-Falek O, Kantor B. Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases. In: MOLECULAR THERAPY. 2026.
Duke, Leanne, et al. “Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases.” MOLECULAR THERAPY, vol. 34, no. 5, 2026.
Duke L, Rittiner J, O’donovan B, Chiba-Falek O, Kantor B. Novel AAV vectors for allele-discriminatory-based, epigenome-editing therapy targeting ApoE4 allele in Alzheimer's Disease (AD) cases. MOLECULAR THERAPY. 2026.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
May 8, 2026
Volume
34
Issue
5
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics